Pethidine Versus Nitrous Oxide for Pain Relief During Labor

Sponsor
HaEmek Medical Center, Israel (Other)
Overall Status
Unknown status
CT.gov ID
NCT02783508
Collaborator
(none)
214
1
2
48
4.5

Study Details

Study Description

Brief Summary

Systematic opioids and inhaled nitrous oxide (N2O ) are common methods for pain relief during labor. The aim of the current study is to evaluate the efficacy of systemic pethidine compared to N2O given for pain relieve in term, multiparous women in labor.

Condition or Disease Intervention/Treatment Phase
  • Drug: IV Meperidine
  • Drug: Nitrous Oxide
N/A

Detailed Description

Pain relief during labor and delivery is an essential part of good obstetrical care. Labor pain and its relief have implications on the course of labor, maternal and fetal outcomes and the satisfaction with childbirth overall. Many women would like to have a choice in pain relief during labor but also would like to avoid invasive methods of pain management in labor (as epidural). Both, inhaled analgesia and parenteral opioids are common pharmacological interventions aim to relieve the pain of labor.Nitrous oxide in a 50/50 mix with oxygen is the most common concentration used for labor pain management. It is self-administered via facemask, intermittently, and has rapid onset and offset effect. Main side effects, including nausea, vomiting, dizziness and drowsiness. Pethidine is one of the most frequently used opiate agonists. It can be given intravenous or intramuscularly. Its analgesic effect starts within 10-20 minutes and lasts 2-4 hours. Reported maternal side effects include nausea, vomiting and dysphoria. Pethidine may lead to changes in fetal heart rate tracing during labor, respiratory depression, impaired sucking reflex and restlessness.

Given the fact that these two routine interventions are given in different ways and have different side effects profile, the investigators aim in this randomized controlled trial to compare the analgesic effect of these two methods and their maternal and perinatal secondary effects in multiparous laboring women.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
214 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Pethidine Versus Nitrous Oxide for Pain Relief During Labor Among Multiparous. A Randomized Controlled Trial
Actual Study Start Date :
Aug 1, 2016
Actual Primary Completion Date :
May 1, 2019
Anticipated Study Completion Date :
Aug 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: IV Meperidine

Intravenous injection of meperidine 50mg given in 100cc NaCl 0.9% over 10 minutes. Repeated doses (if needed) will be given in intervals of 2 hours minimum until a maximum of 4 doses.

Drug: IV Meperidine
Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses. In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient. If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered.
Other Names:
  • Pethidine
  • Active Comparator: Inhaled Nitrous Oxide

    Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, the parturient will be advised not to breath through the mask.

    Drug: Nitrous Oxide
    Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask. In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient. If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered.
    Other Names:
  • N2O
  • Outcome Measures

    Primary Outcome Measures

    1. Pain intensity [20-30 minutes after drug administration.]

      Visual analogue scale

    Secondary Outcome Measures

    1. Pain intensity [60, 120 and 180 minutes from drug administration.]

      Visual analogue scale

    2. Time from drug administration to labor. [24 hours]

    3. Need for additional analgesia [24 hours]

      Number of women that needed additional analgesia.

    4. Side effects. [During 60 minutes from drug administration.]

      nausea, vomiting, itching, headache, mouth dryness, drowsiness

    5. Breast feeding [Up to 48 hours after birth]

    6. Participants satisfaction and the usefulness of pain relief [Within 48 hours after birth]

      Scale of excellent, very good, good, fair or poor.

    7. Changes in electronic fetal heart rate monitoring [24 hours]

    8. Occurence of meconium stained amniotic fluid [24 hours]

      Number of women with meconium stained amniotic fluid.

    9. Umbilical artery PH [Up to 5 min from birth, after performing cord clamping.]

      Number of women with Umbilical artery PH less than 7.1.

    10. Apgar score [At 1 and 5 minutes after birth]

    11. Need for respiration [Within 48 hours after birth]

    12. Neonatal Intensive Care Unit (NICU) administration [Within 48 hours after birth]

      Number of neonates that admitted to neonatal intensive care unit within 48 hours after birth.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Multiparity (para 2 or more).

    2. Term pregnancy: 37-42 weeks of gestation.

    3. Singleton pregnancy.

    4. Vertex presentation.

    5. In labor: at least 2 contraction in ten minutes and cervical dilatation of 2 centimeters or more.

    Exclusion Criteria:
    1. Women who desire epidural as a first line analgesia during labor.

    2. Women receiving pethidine during the last 24 hours (prior to entering labor room).

    3. Contra-indication for vaginal delivery.

    4. Contra-indication or allergic reaction to either pethidine or nitrous oxide.

    5. History of drug abuse.

    6. Previous cesarean delivery.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 HaEmek Medical Center Afula Israel 18101

    Sponsors and Collaborators

    • HaEmek Medical Center, Israel

    Investigators

    • Study Chair: Raed Salim, MD, haemek medical center
    • Principal Investigator: Sivan Easton, MD, haemek medical center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Sivan Easton, Medical Doctor, HaEmek Medical Center, Israel
    ClinicalTrials.gov Identifier:
    NCT02783508
    Other Study ID Numbers:
    • 0072-016-EMC
    First Posted:
    May 26, 2016
    Last Update Posted:
    Feb 12, 2020
    Last Verified:
    Feb 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Sivan Easton, Medical Doctor, HaEmek Medical Center, Israel
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 12, 2020